Overview
Ga³⁺-Ciprofloxacin is a prototype antibacterial MDC developed to overcome conventional resistance mechanisms. By incorporating Gallium (Ga³⁺), this complex mimics iron transport systems and disrupts bacterial iron metabolism, enhancing membrane penetration and intracellular uptake.
Mechanism of Action
- Ga³⁺ competitively inhibits bacterial iron acquisition systems
- Ciprofloxacin maintains topoisomerase inhibition while exhibiting improved cellular entry
- Disrupts membrane integrity via ROS amplification
Key Properties
- Enhanced uptake in Gram-negative strains
- Reduced emergence of resistance under serial passage
- High solubility and formulation stability
Application
Therapeutic Class: Antibiotics
Suggested use in acute bacterial infections where resistance risk is high (e.g., urinary tract infections, respiratory pathogens).
Antibacterial
Reduced Resistance
Development Stage
Advanced Preclinical
Further Information
For licensing details, compound data sheets, or experimental protocols, contact our research team.
Contact Us